## Cyamemazine-d<sub>6</sub>

Cat. No.:HY-14264SCAS No.:1216608-24-0Molecular Formula:C1,9H,5D,0N,SMolecular Weight:329.49Target:5-HT Receptor; Isotope-Labeled CompoundsPathway:GPCR/G Protein; Neuronal Signaling; OthersStorage:Please store the product under the recommended conditions in the Certificate of			
Molecular Formula:   C19H15D6N3S     Molecular Weight:   329.49     Target:   5-HT Receptor; Isotope-Labeled Compounds     Pathway:   GPCR/G Protein; Neuronal Signaling; Others	Cat. No.:	HY-14264S	_ D _
Molecular Weight: 329.49   Target: 5-HT Receptor; Isotope-Labeled Compounds   Pathway: GPCR/G Protein; Neuronal Signaling; Others	CAS No.:	1216608-24-0	D
Target: 5-HT Receptor; Isotope-Labeled Compounds   Pathway: GPCR/G Protein; Neuronal Signaling; Others	Molecular Formula:	C <sub>19</sub> H <sub>15</sub> D <sub>6</sub> N <sub>3</sub> S	DN_
Pathway: GPCR/G Protein; Neuronal Signaling; Others	Molecular Weight:	329.49	
	Target:	5-HT Receptor; Isotope-Labeled Compounds	
Storage: Please store the product under the recommended conditions in the Certificate of	Pathway:	GPCR/G Protein; Neuronal Signaling; Others	
Analysis.	Storage:		s

∭N

BIOLOGICAL ACTIVITY				
Description	Cyamemazine-d <sub>6</sub> is the deuterium labeled Cyamemazine. Cyamemazine is a neuroleptic agent that contains the phenothiazine chromophore. Cyamemazine is often used as an anxiolytic. Cyamemazine is a potent 5-HT3 (Ki of 12 nM), 5-HT2A (Ki = 1.5 nM) and 5-HT2C (Ki of 75 nM) receptors antagonist with antipsychotic activity[1][2].			
In Vitro	Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.			

## REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

[2]. Bourin M, et al. Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome. CNS Drug Rev. 2004 Fall;10(3):219-29.

[3]. Vendrell-Criado V, et al. Photobehavior of the antipsychotic drug cyamemazine in a supramolecular gel protective environment. J Photochem Photobiol B. 2020 Jan;202:111686.

Caution: Product has not been fully validated for medical applications. For research use only.

Fax: 609-228-5909 Tel: 609-228-6898

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

**Product** Data Sheet

